Clinical trial NCT05203055: Peginterferon Alpha-2b Therapy in Chronic Hepatitis Patients With Normal ALT Level and Low Viremia
Official title: A Multi-center, Open-label Study to Elucidate the Efficacy and Safety of Peginterferon Alpha-2b Therapy in the Initial Treatment of Chronic Hepatitis Patients With Normal ALT Level and Low Viremia
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Chronic Hepatitis B Patients With a Normal ALT Level and Low Viremia
Lead sponsor: Fuzhou General Hospital
Sponsor class: OTHER
First posted: 2022-01-24
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To date, antiviral treatment is not recommended for chronic hepatitis B patients with a normal ALT level and low viremia. The strategy is to closely monitor the patients. However, evidence suggests that these group are at risk of gradual disease progression and development of hepatocellular carcinoma. Peginterferon eliminates the hepatitis B virus through immune regulation and induction of antiviral protein expression. For patients with low viral load, the clinical cure rate is potentially promising. In this study, we aim to investigate the efficacy and safety of peginterferon alpha-2b therapy in selected chronic hepatitis B patients with normal ALT level and low viremia. It is expected to obtain a satisfactory curative effect. Peginterferon is a marketed drug available in Chinese clinics with indications of anti-hepatitis B virus.


Eligibility criteria: Inclusion Criteria:

1. willing to receive the treatment and sign informed consent;
2. 18-60 years old (including 18 and 60), both gender;
3. HBsAg positive for at least 6 months and \<1500IU/ml;
4. ALT≤1xULN and no elevated ALT has been detected in history;
5. HBV DNA detectable but\<2000 IU/ml;
6. HBeAg negative ;

Exclusion Criteria:

1. For female participants: positive pregnancy test, presently breast-feeding, or unwillingness to use effective contraceptive measures for the duration of the study. For male participants: intent to procreate 3 months before or after the intervention or unwillingness to use effective measures of the contraception ;
2. neuropsychiatric diseases, such as depression, anxiety, mania, schizophrenia, or a family history of mental illness (especially with a history of depression or depression tendency);
3. co-infection of HCV, EBV, other hepatotropic viruses , non-hepatotropic viruses;
4. alcoholic hepatitis, drug-induced hepatitis, autoimmune liver disease;
5. Patients with moderate to severe steatohepatitis;
6. possibility of liver cirrhosis that cannot be excluded
7. hepatocellular carcinoma or AFP level\>30ng/ml;
8. Kidney diseases: acute and chronic nephritis, renal insufficiency, nephrotic syndrome, serum creatinine\> 1 x ULN at the time of screening;
9. at screening, the neutrophil count is less than 1.5×10\^9/L, and the platelet count is less than 90×10\^9/L;
10. Serum phosphorus level \<0.7 mmol/L;
11. Antinuclear antibody (ANA)\>1:100;
12. Autoimmune diseases, including thyroiditis, psoriasis and systemic lupus erythematosus;
13. Endocrine system diseases, including thyroid diseases and diabetes mellitus;
14. Uncontrolled blood pressure: SBP\>160 mmHg or DBP \>100 mmHg at the time of enrollment;
15. Evidence of cardiovascular disease, existing congestive cardiac failure on physical exam and/or acute coronary syndrome in the past 6 months;
16. Severe retinopathy or other serious eye diseases;
17. Organic disease or dysfunction;
18. plan to receive an organ transplant or have already undergone an organ transplant;
19. received standardized treatment with interferon or NA products before .
20. allergic to interferon or pharmaceutical excipients, or meet any of the contraindications in the experimental drug instructions;
21. Participated in other interventional trials within 3 months before the screening or other conditions deemed unsuitable by the investigator.

Primary outcomes:
measure: The percentage of patients with undetectable HBV DNA
timeFrame: week 24
measure: HBsAg clearance rate
timeFrame: week 48
measure: HBsAg conversion rate
timeFrame: week 48
Secondary outcomes:
measure: The percentage of patients with undetectable HBV DNA
timeFrame: week 24 and week 48
measure: The HBsAg level
timeFrame: week 24 and week 48
measure: The HBV pgRNA level
timeFrame: week 24 and week 48
Other outcomes:
Locations:
city: Fuzhou
country: China
facility: Fuzhou General Hospital, Xiamen Univ
state: Fujian
Study officials:
References: